Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
7.10
+0.03 (0.42%)
Mar 31, 2025, 12:34 PM EDT - Market open

Contineum Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-42.2622.72-24.25-29
Depreciation & Amortization
0.260.20.330.33
Other Amortization
---0.15
Loss (Gain) From Sale of Assets
-0.02-0-
Loss (Gain) From Sale of Investments
-3.95-2.660.250.39
Stock-Based Compensation
6.82.221.931.75
Other Operating Activities
0.98-2.112.90.01
Change in Accounts Payable
1.14--0.23-0.11
Change in Other Net Operating Assets
4.19-1.02-1.040.22
Operating Cash Flow
-32.8519.35-20.12-26.27
Capital Expenditures
-0.51-0.41-0.12-0.17
Sale of Property, Plant & Equipment
0.02---
Investment in Securities
-69.25-65.1522.42-64.8
Investing Cash Flow
-69.74-65.5722.3-64.97
Long-Term Debt Repaid
--3.75-1.25-
Net Debt Issued (Repaid)
--3.75-1.25-
Issuance of Common Stock
1090.160.020.11
Repurchase of Common Stock
--0.03-0-
Other Financing Activities
--0.34--
Financing Cash Flow
10956.18-1.2479.84
Net Cash Flow
6.429.960.94-11.4
Free Cash Flow
-33.3618.94-20.24-26.43
Free Cash Flow Margin
-37.87%--
Free Cash Flow Per Share
-1.725.58-9.02-12.53
Cash Interest Paid
-0.150.230.22
Cash Income Tax Paid
-0.45--
Levered Free Cash Flow
-20.8713.08-12.61-
Unlevered Free Cash Flow
-20.8713.21-12.37-
Change in Net Working Capital
-4.39-1.170.31-
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q